De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
17 03 2022
17 03 2022
Historique:
received:
26
11
2021
accepted:
28
02
2022
entrez:
18
3
2022
pubmed:
19
3
2022
medline:
5
4
2022
Statut:
epublish
Résumé
SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. We present a case of an immunocompromised patient with acquired B-cell deficiency who developed an indolent, protracted course of SARS-CoV-2 infection. Remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. Whole genome sequencing identified a mutation, E802D, in the nsp12 RNA-dependent RNA polymerase, which was not present in pre-treatment specimens. In vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir IC
Identifiants
pubmed: 35301314
doi: 10.1038/s41467-022-29104-y
pii: 10.1038/s41467-022-29104-y
pmc: PMC8930970
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
imdevimab
2Z3DQD2JHM
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Coronavirus RNA-Dependent RNA Polymerase
EC 2.7.7.48
NSP12 protein, SARS-CoV-2
EC 2.7.7.48
casirivimab
J0FI6WE1QN
Alanine
OF5P57N2ZX
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1547Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007517
Pays : United States
Organisme : U.S. Department of Health & Human Services | National Institutes of Health (NIH)
ID : 2T32AI007517-21A1
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2022. The Author(s).
Références
Nat Protoc. 2021 Mar;16(3):1761-1784
pubmed: 33514944
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Cell. 2021 May 13;184(10):2605-2617.e18
pubmed: 33831372
PLoS Biol. 2021 May 7;19(5):e3001236
pubmed: 33961632
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Nat Commun. 2021 Jan 12;12(1):279
pubmed: 33436624
Bioinformatics. 2011 Nov 1;27(21):2987-93
pubmed: 21903627
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33046529
Nat Commun. 2020 Dec 14;11(1):6385
pubmed: 33318491
Science. 2020 Jun 26;368(6498):1499-1504
pubmed: 32358203
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750
Viruses. 2021 Jun 23;13(7):
pubmed: 34201591
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
PLoS Pathog. 2021 Sep 17;17(9):e1009929
pubmed: 34534263
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
Clin Infect Dis. 2021 Oct 5;73(7):e1762-e1765
pubmed: 32986807
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Ann Oncol. 2020 Oct;31(10):1418-1419
pubmed: 32615155
Mol Biol Evol. 2007 Aug;24(8):1586-91
pubmed: 17483113
Cell. 2021 Jan 7;184(1):76-91.e13
pubmed: 33147444
Nat Commun. 2020 Nov 27;11(1):6059
pubmed: 33247099
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066